Skip to main
SIBN

SI-BONE Inc (SIBN) Stock Forecast & Price Target

SI-BONE Inc (SIBN) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

SI-BONE Inc. demonstrated a robust financial performance in the second quarter of 2025, with revenue increasing by approximately 23% year-over-year to reach $46.4 million, reflecting strong demand for its innovative surgical implant products. Additionally, the company's gross margin improved by about 80 basis points compared to the previous year, attaining a level of 79.8%, which indicates efficient cost management and product profitability. Furthermore, an upward revision of the 2025 revenue estimate to $196.5 million, from a prior estimate of $193.9 million, underscores the company's positive trajectory driven by enhanced sales productivity and surgeon engagement.

Bears say

The financial outlook for SI-BONE Inc. is negatively affected by ongoing pricing pressures and procedural headwinds in the global spine market, leading to growth rates that have stagnated in the low-single digits. Additionally, competitive products may gain traction in the marketplace, potentially reducing SI-BONE's market share in sacroiliac joint fusion procedures, thereby negatively impacting revenue performance. Furthermore, SI-BONE's enterprise value-to-sales growth ratio of 0.19x falls significantly short of the median of 0.34x for its small to mid-cap growth peer group, indicating a relative undervaluation compared to its competitors.

SI-BONE Inc (SIBN) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About SI-BONE Inc (SIBN) Forecast

Analysts have given SI-BONE Inc (SIBN) a Buy based on their latest research and market trends.

According to 6 analysts, SI-BONE Inc (SIBN) has a Buy consensus rating as of Jan 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

SI-BONE Inc (SIBN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.